Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

MLA

Desmond Y. H. Yap, et al. “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers.” Clinical and Translational Science, vol. 14, no. 5, Sept. 2021, pp. 1769–79. EBSCOhost, https://doi.org/10.1111/cts.13019.

APA

Desmond Y. H. Yap, Jojo Hai, Paul C. H. Lee, Xueying Zhou, Michael Lee, Yu Zhang, Meng Wang, & Xiaoxiang Chen. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clinical and Translational Science, 14(5), 1769–1779. https://doi.org/10.1111/cts.13019

Chicago

Desmond Y. H. Yap, Jojo Hai, Paul C. H. Lee, Xueying Zhou, Michael Lee, Yu Zhang, Meng Wang, and Xiaoxiang Chen. 2021. “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers.” Clinical and Translational Science 14 (5): 1769–79. doi:10.1111/cts.13019.